Trademark: 97842013
Word
NUCLEIX
Status Date
Thursday, January 4, 2024
Filing Date
Thursday, March 16, 2023
5 Diagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection or detection of or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; diagnostic reagents for medical purposes
1 Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use
44 Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing cancer screening services; providing screening services for chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease
42 Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays
The mark consists of the term NUCLEIX in a stylized format with the letter "I" inverted such that the dot appears below the word.
Color is not claimed as a feature of the mark.
Jan 4, 2024
Notification Of Non-Final Action E-Mailed
Jan 4, 2024
Non-Final Action E-Mailed
Jan 4, 2024
Non-Final Action Written
Dec 13, 2023
Assigned To Examiner
Apr 7, 2023
Notice Of Design Search Code E-Mailed
Apr 6, 2023
New Application Office Supplied Data Entered
Mar 20, 2023
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
